Hepatitis B virus (HBV) infection is a leading cause of liver damage and hepatic
inflammation. Upon infection, effective antiviral responses by CD8+ T cells, CD4+ T cells …

Hepatitis B virus (HBV) infection is a worldwide health problem, with approximately one third
of populations have been infected, among which 3–5% of adults and more than 90% of …

Hepatitis B virus (HBV) infection has a low rate of chronicity compared to HCV infection, but
chronic liver inflammation can evolve to life threatening complications. Experimental data …

Approximately 400 million people are chronically infected with hepatitis B virus (HBV)
globally despite the widespread immunization of HBV vaccine and the development of …

The hepatitis B virus (HBV) infects hepatocytes, which are the main cell type composing a
human liver. However, the liver is enriched with immune cells, particularly innate cells (eg …

Hepatitis B virus (HBV) is a noncytopathic virus that causes liver disease of variable duration
and severity. It is widely assumed that during HBV infection the host immune response is …

Hepatitis B virus (HBV) infection is a non‐cytopathic hepatotropic virus that can lead to
severe liver disease including acute hepatitis, cirrhosis and hepatocellular carcinoma …

Hepatitis B virus (HBV) is a major cause of acute and chronic hepatitis in humans. As HBV
itself is currently viewed as a non-cytopathic virus, the liver pathology associated with …

Hepatitis B virus (HBV) infection remains a major public health problem worldwide with more
than 240 million individuals chronically infected. Current treatments can control HBV …

Hepatitis B virus (HBV) is a hepatotropic DNA virus and its infection results in acute or
chronic hepatitis. It is reported that the host innate immune system contributes to viral control …